Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print

Lilly Appoints Emerging Markets SVP



Published October 25, 2013
Related Searches: Development
Alfonso "Chito" Zulueta has been promoted to senior vice president and president of the Emerging Markets business at Eli Lilly and Co., effective Jan. 1, 2014. Mr. Zulueta replaces Jacques Tapiero who will retire after 31 years with the company.
 
Mr. Zulueta has served as president and general manager of Lilly Japan since 2008. In his new role, he will lead the company's efforts in the growing markets of Asia, Latin America, Middle East and Africa, as well as Russia and Turkey. Mr. Zulueta reports to John Lechleiter, Ph.D., chairman, president, and chief executive officer, and will serve on the company's executive committee.
 
Mr. Tapiero joined Lilly in 1983 as a financial analyst and became president of Emerging Markets in 2009. Prior to that, he had served as president of the intercontinental region for Lilly with offices in Asia, Australia, Africa, the Middle East, Canada, Latin America, and Russia, and had been general manager of several affiliates.
 
"Jacques Tapiero has made extraordinary contributions to our company throughout his 31-year career with Lilly, culminating in 2009 with his appointment to lead our important Emerging Markets business," said Mr. Lechleiter. "Jacques' leadership has been characterized by strong operational skills and a keen focus on the development of Lilly people around the world. Jacques has been an exemplar of our values of integrity, excellence, and respect for people."
 
"I am delighted to welcome Chito Zulueta to the company's top management team," Mr. Lechleiter added. "Chito's previous Lilly assignments have provided him with the global experience necessary for his new role as head of our Emerging Markets business. Chito's business savvy, his insights into diverse markets and cultures, and his passion for the patients whom we serve have enabled him to deliver outstanding results throughout his career. He is the ideal candidate to assume this important position."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On